he4test.comHE4 a novel biomarker - Improved management of ovarian malignancy

Skip to main content Google Tag Manager United States Choose your country Select your country Rest Of World United States Remember my choice every time I come back Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country. Home Monitoring - HE4 Risk Algorithm - ROMA Case Studies Education and Events Insights Test Availability Contact In 2022, it is expected that there will be approximately 19,880 new ovarian cancer cases in the United States, and 12,812 women will die from ovarian cancer. 1 The five-year survival rate is 92% for women with stage I epithelial ovarian cancers. However, survival rates decline dramatically to 17% to 28% for those with advanced-stage tumors. 2 CA125, is commonly used to evaluate patients for ovarian cancer, which can be problematic given that CA125 is elevated in benign conditions such as endometriosis and other gynecologic conditions. 3 In the US, approximately 200,000 women will undergo surgery for an ovarian cyst or adnexal mass and 80% to 90% of these women will be diagnosed with benign disease. References American Cancer Society. Key Statistics for Ovarian cancer 2022. https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html#written_by . Accessed January 25, 2021. Doubeni CA, Doubeni AR, Myers AE. Diagnosis and Management of Ovarian Cancer. Am Fam Physician. 2016;93(11):937-944. Glanc, P, Benacerraf B, Bourne T, et al. First International Consensus Report on Adnexal Masses: Management Recommendations. J Ultrasound Med. 2017;36: 849-863. Contact Privacy policy Terms & Conditions FDI-546 09/19 Close Home Monitoring - HE4 Risk Algorithm - ROMA Case Studies Education and Events Insights Test Availability...